Preoperative Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2)
OBJECTIVES: I. Assess the efficacy and toxic effects of docetaxel plus cisplatin in patients
with stage IIIA non-small cell lung cancer. II. Assess the clinical and pathological
response rate to this therapy in this patient population. III. Compare the benefit of
surgery in terms of overall survival of responding and nonresponding patients.
OUTLINE: Patients receive infusions of docetaxel over 1 hour on day 1, followed by infusions
of cisplatin over 1 hour on days 1-2. Treatment is repeated for three 21 day courses.
Patients undergo tumor resection and mediastinal lymph node dissection. Patients are to
receive postoperative radiotherapy within 4 weeks of resection if the tumor reaches the
resection margins and/or the first mediastinal lymph node levels are involved. Patients will
be followed until death.
PROJECTED ACCRUAL: Approximately 5-40 patients will be accrued within 3 years.
Primary Purpose: Treatment
Daniel C. Betticher, MD
University Hospital Inselspital, Berne